Cisplatin Concentrations in Long and Short Duration Infusion: Implications for the Optimal Time of Radiation Delivery

Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiatio...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical and diagnostic research Vol. 10; no. 7; pp. XC01 - XC04
Main Author Rajkumar, Pradeep
Format Journal Article
LanguageEnglish
Published India JCDR Research and Publications (P) Limited 01.07.2016
JCDR Research and Publications Private Limited
Subjects
Online AccessGet full text
ISSN2249-782X
0973-709X
DOI10.7860/JCDR/2016/18181.8126

Cover

Abstract Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiation is unclear. The aim of this study was to measure the two cisplatin infusion regimens in order to determine the total and free cisplatin post infusion concentration changes over time. These changes may have clinical implications on the optimum time of administration of post infusion radiation therapy. Two cohorts of patients were recruited and both, total and free plasma concentration of cisplatin following long and short durations of intravenous infusion was determined. Blood samples were collected at 0.5, 1, 1.5, 2, 3 and 5 hours from the start of the infusion in the 1hour infusion group and at 2, 3, 3.5, 4, 6 and 24 hours from the start of the infusion, in the 3 hour infusion group. Total and free cisplatin concentrations were measured using a validated HPLC-UV method. The highest concentration of total and free cisplatin was achieved at the end of the infusion in both regimens. Total cisplatin concentration declined 30 minutes after the end of infusion in both the groups. After 1hour of discontinuing cisplatin, the free cisplatin concentration also declined significantly. We conclude that radiation should be administered within 30 minutes of completion of the infusion irrespective of the duration of infusion.
AbstractList Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiation is unclear.INTRODUCTIONCisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiation is unclear.The aim of this study was to measure the two cisplatin infusion regimens in order to determine the total and free cisplatin post infusion concentration changes over time. These changes may have clinical implications on the optimum time of administration of post infusion radiation therapy.AIMThe aim of this study was to measure the two cisplatin infusion regimens in order to determine the total and free cisplatin post infusion concentration changes over time. These changes may have clinical implications on the optimum time of administration of post infusion radiation therapy.Two cohorts of patients were recruited and both, total and free plasma concentration of cisplatin following long and short durations of intravenous infusion was determined. Blood samples were collected at 0.5, 1, 1.5, 2, 3 and 5 hours from the start of the infusion in the 1hour infusion group and at 2, 3, 3.5, 4, 6 and 24 hours from the start of the infusion, in the 3 hour infusion group. Total and free cisplatin concentrations were measured using a validated HPLC-UV method.MATERIALS AND METHODSTwo cohorts of patients were recruited and both, total and free plasma concentration of cisplatin following long and short durations of intravenous infusion was determined. Blood samples were collected at 0.5, 1, 1.5, 2, 3 and 5 hours from the start of the infusion in the 1hour infusion group and at 2, 3, 3.5, 4, 6 and 24 hours from the start of the infusion, in the 3 hour infusion group. Total and free cisplatin concentrations were measured using a validated HPLC-UV method.The highest concentration of total and free cisplatin was achieved at the end of the infusion in both regimens. Total cisplatin concentration declined 30 minutes after the end of infusion in both the groups. After 1hour of discontinuing cisplatin, the free cisplatin concentration also declined significantly.RESULTSThe highest concentration of total and free cisplatin was achieved at the end of the infusion in both regimens. Total cisplatin concentration declined 30 minutes after the end of infusion in both the groups. After 1hour of discontinuing cisplatin, the free cisplatin concentration also declined significantly.We conclude that radiation should be administered within 30 minutes of completion of the infusion irrespective of the duration of infusion.CONCLUSIONWe conclude that radiation should be administered within 30 minutes of completion of the infusion irrespective of the duration of infusion.
Introduction: Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiation is unclear. Aim: The aim of this study was to measure the two cisplatin infusion regimens in order to determine the total and free cisplatin post infusion concentration changes over time. These changes may have clinical implications on the optimum time of administration of post infusion radiation therapy. Materials and Methods: Two cohorts of patients were recruited and both, total and free plasma concentration of cisplatin following long and short durations of intravenous infusion was determined. Blood samples were collected at 0.5, 1, 1.5, 2, 3 and 5 hours from the start of the infusion in the 1hour infusion group and at 2, 3, 3.5, 4, 6 and 24 hours from the start of the infusion, in the 3 hour infusion group. Total and free cisplatin concentrations were measured using a validated HPLC-UV method. Results: The highest concentration of total and free cisplatin was achieved at the end of the infusion in both regimens. Total cisplatin concentration declined 30 minutes after the end of infusion in both the groups. After 1hour of discontinuing cisplatin, the free cisplatin concentration also declined significantly. Conclusion: We conclude that radiation should be administered within 30 minutes of completion of the infusion irrespective of the duration of infusion.
Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiation is unclear. The aim of this study was to measure the two cisplatin infusion regimens in order to determine the total and free cisplatin post infusion concentration changes over time. These changes may have clinical implications on the optimum time of administration of post infusion radiation therapy. Two cohorts of patients were recruited and both, total and free plasma concentration of cisplatin following long and short durations of intravenous infusion was determined. Blood samples were collected at 0.5, 1, 1.5, 2, 3 and 5 hours from the start of the infusion in the 1hour infusion group and at 2, 3, 3.5, 4, 6 and 24 hours from the start of the infusion, in the 3 hour infusion group. Total and free cisplatin concentrations were measured using a validated HPLC-UV method. The highest concentration of total and free cisplatin was achieved at the end of the infusion in both regimens. Total cisplatin concentration declined 30 minutes after the end of infusion in both the groups. After 1hour of discontinuing cisplatin, the free cisplatin concentration also declined significantly. We conclude that radiation should be administered within 30 minutes of completion of the infusion irrespective of the duration of infusion.
Author Rajkumar, Pradeep
AuthorAffiliation 3 Associate Professor, Department of Radiation Oncology, Christian Medical College Hospital , Vellore, India
4 Associate Professor, Department of Radiation Oncology, Christian Medical College Hospital , Vellore, India
1 Fellow, Clinical Pharmacology Unit, Department of Pharmacology and Clinical Pharmacology, Christian Medical College Hospital , Vellore, India
5 Professor, Department of Radiation Oncology, Christian Medical College Hospital , Vellore, India
6 Assistant Professor, Clinical Pharmacology Unit, Christian Medical College Hospital , Vellore, India
7 Professor, Clinical Pharmacology Unit, Christian Medical College Hospital , Vellore, India
2 Professor, Clinical Pharmacology Unit, Department of Pharmacology and Clinical Pharmacology, Christian Medical College Hospital , Vellore, India
AuthorAffiliation_xml – name: 6 Assistant Professor, Clinical Pharmacology Unit, Christian Medical College Hospital , Vellore, India
– name: 1 Fellow, Clinical Pharmacology Unit, Department of Pharmacology and Clinical Pharmacology, Christian Medical College Hospital , Vellore, India
– name: 7 Professor, Clinical Pharmacology Unit, Christian Medical College Hospital , Vellore, India
– name: 3 Associate Professor, Department of Radiation Oncology, Christian Medical College Hospital , Vellore, India
– name: 5 Professor, Department of Radiation Oncology, Christian Medical College Hospital , Vellore, India
– name: 4 Associate Professor, Department of Radiation Oncology, Christian Medical College Hospital , Vellore, India
– name: 2 Professor, Clinical Pharmacology Unit, Department of Pharmacology and Clinical Pharmacology, Christian Medical College Hospital , Vellore, India
Author_xml – sequence: 1
  givenname: Pradeep
  surname: Rajkumar
  fullname: Rajkumar, Pradeep
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27630935$$D View this record in MEDLINE/PubMed
BookMark eNp9Uk1vGyEQRVWqxkn7D6qKYy-O-YbNoVJlp4krS5HSVMoNsSxrE63Bhd1I-ffFXqdqeqg4ADPvvYGZdwZOQgwOgI8YXUgl0Oz7fHE3IwiLGVZlXShMxBswQZWkU4mqhxMwIYRVU6nIwyk4y_kRISEEFe_AKZGCooryCRjmPu860_sA5zFYF_pULjFkWCKrGNbQhAb-2MTUw8Uw5uAytEMuh0u43O46b4-MNibYbxy83fV-azp477cOxhbemcaPxIXr_JNLz-_B29Z02X047ufg57er-_nNdHV7vZx_XU0tk6yfEkbaqqotds5yYrEiAgnjGmWdI0whLGmFHBfUcCIwa2tLcSN5XTtTOyENPQfLUbeJ5lHvUnlWetbReH0IxLTWJvXedk4jJClXymDGaiapqRQiSkmu6qbmiMqi9WXU2g311jVjq7pXoq8zwW_0Oj5pjsqUKlYEPh8FUvw1uNzrrc_WdZ0JLg5Zl-8hXgnCSYF--rvWnyIvcyuAyxFgU8w5uVZb3x96XEr7TmOk9ybRe5PovUn0wSR6b5JCZv-QX_T_S_sNuDTBEQ
CitedBy_id crossref_primary_10_7554_eLife_56235
crossref_primary_10_1080_10937404_2021_1884921
crossref_primary_10_1172_jci_insight_171140
crossref_primary_10_3389_fonc_2021_750677
crossref_primary_10_3389_fphar_2022_879748
crossref_primary_10_1021_acs_chemrestox_6b00389
crossref_primary_10_26599_NBE_2023_9290008
crossref_primary_10_1021_acs_jmedchem_4c02373
crossref_primary_10_1186_s12885_017_3864_6
crossref_primary_10_14814_phy2_14927
crossref_primary_10_3389_fonc_2023_1212604
ContentType Journal Article
Copyright 2016 Journal of Clinical and Diagnostic Research 2016
Copyright_xml – notice: 2016 Journal of Clinical and Diagnostic Research 2016
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.7860/JCDR/2016/18181.8126
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ (Directory of Open Access Journals)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 0973-709X
EndPage XC04
ExternalDocumentID oai_doaj_org_article_0073588a144b473a980288758bdb5037
PMC5020194
27630935
10_7860_JCDR_2016_18181_8126
Genre Journal Article
GroupedDBID ---
2WC
5VS
AAYXX
ABDBF
ACUHS
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BCNDV
CITATION
DIK
E3Z
EBD
EOJEC
ESX
GROUPED_DOAJ
GX1
HYE
KQ8
M~E
OBODZ
OK1
P6G
RNS
RPM
TR2
TUS
~8M
NPM
7X8
5PM
ID FETCH-LOGICAL-c474t-242f99bc1eec52c182606aed8cee248017390e563a52614fbc31d75bbeabe67a3
IEDL.DBID DOA
ISSN 2249-782X
IngestDate Wed Aug 27 01:31:17 EDT 2025
Thu Aug 21 18:43:14 EDT 2025
Thu Jul 10 17:36:10 EDT 2025
Thu Jan 02 22:26:27 EST 2025
Tue Jul 01 01:23:23 EDT 2025
Thu Apr 24 23:10:31 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords Radiosensitizing
Chemotherapy
Radiation therapy
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c474t-242f99bc1eec52c182606aed8cee248017390e563a52614fbc31d75bbeabe67a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doaj.org/article/0073588a144b473a980288758bdb5037
PMID 27630935
PQID 1820596252
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_0073588a144b473a980288758bdb5037
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5020194
proquest_miscellaneous_1820596252
pubmed_primary_27630935
crossref_citationtrail_10_7860_JCDR_2016_18181_8126
crossref_primary_10_7860_JCDR_2016_18181_8126
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-07-01
PublicationDateYYYYMMDD 2016-07-01
PublicationDate_xml – month: 07
  year: 2016
  text: 2016-07-01
  day: 01
PublicationDecade 2010
PublicationPlace India
PublicationPlace_xml – name: India
– name: Delhi, India
PublicationTitle Journal of clinical and diagnostic research
PublicationTitleAlternate J Clin Diagn Res
PublicationYear 2016
Publisher JCDR Research and Publications (P) Limited
JCDR Research and Publications Private Limited
Publisher_xml – name: JCDR Research and Publications (P) Limited
– name: JCDR Research and Publications Private Limited
References 21621941 - J Pharm Biomed Anal. 2011 Aug 25;56(1):126-30
2254110 - Int J Radiat Oncol Biol Phys. 1990 Nov;19(5):1183-9
8573645 - J Pharm Biomed Anal. 1995 Aug;13(9):1173-8
8003553 - J Pharm Biomed Anal. 1994 Feb;12(2):265-71
2364368 - Cancer. 1990 Aug 1;66(3):564-9
14645636 - N Engl J Med. 2003 Nov 27;349(22):2091-8
12899503 - Acta Oncol. 2003;42(4):315-25
9614438 - Jpn J Clin Oncol. 1998 Mar;28(3):168-75
15151521 - Br J Clin Pharmacol. 2004 Jun;57(6):756-63
25793192 - Biomed Res Int. 2015;2015:307576
2824080 - Cancer Chemother Pharmacol. 1987;20(3):211-2
16181764 - J Pharm Biomed Anal. 2006 Mar 3;40(4):833-9
9466668 - Int J Cancer. 1998 Feb 9;75(4):635-42
2045298 - Int J Radiat Oncol Biol Phys. 1991 Jun;20(6):1235-41
3943271 - Clin Pharmacol Ther. 1986 Feb;39(2):136-44
16861770 - Phys Med Biol. 2006 Aug 7;51(15):3625-37
15068570 - J Anal Toxicol. 2004 Mar;28(2):138-40
References_xml – reference: 21621941 - J Pharm Biomed Anal. 2011 Aug 25;56(1):126-30
– reference: 9614438 - Jpn J Clin Oncol. 1998 Mar;28(3):168-75
– reference: 16861770 - Phys Med Biol. 2006 Aug 7;51(15):3625-37
– reference: 15151521 - Br J Clin Pharmacol. 2004 Jun;57(6):756-63
– reference: 8003553 - J Pharm Biomed Anal. 1994 Feb;12(2):265-71
– reference: 3943271 - Clin Pharmacol Ther. 1986 Feb;39(2):136-44
– reference: 2045298 - Int J Radiat Oncol Biol Phys. 1991 Jun;20(6):1235-41
– reference: 12899503 - Acta Oncol. 2003;42(4):315-25
– reference: 16181764 - J Pharm Biomed Anal. 2006 Mar 3;40(4):833-9
– reference: 14645636 - N Engl J Med. 2003 Nov 27;349(22):2091-8
– reference: 25793192 - Biomed Res Int. 2015;2015:307576
– reference: 2364368 - Cancer. 1990 Aug 1;66(3):564-9
– reference: 2254110 - Int J Radiat Oncol Biol Phys. 1990 Nov;19(5):1183-9
– reference: 15068570 - J Anal Toxicol. 2004 Mar;28(2):138-40
– reference: 8573645 - J Pharm Biomed Anal. 1995 Aug;13(9):1173-8
– reference: 9466668 - Int J Cancer. 1998 Feb 9;75(4):635-42
– reference: 2824080 - Cancer Chemother Pharmacol. 1987;20(3):211-2
SSID ssj0066636
Score 2.2562218
Snippet Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge...
Introduction: Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage XC01
SubjectTerms chemotherapy
Oncology Section
radiation therapy
radiosensitizing
Title Cisplatin Concentrations in Long and Short Duration Infusion: Implications for the Optimal Time of Radiation Delivery
URI https://www.ncbi.nlm.nih.gov/pubmed/27630935
https://www.proquest.com/docview/1820596252
https://pubmed.ncbi.nlm.nih.gov/PMC5020194
https://doaj.org/article/0073588a144b473a980288758bdb5037
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQDxUXBJRCeFSuxDVsEsexzQ12-1RbpJZKe7Nsx6GVirdiNwf-PTN2drVbIfXSyx7yUCzP2N83O-NvCPmsOIBu4ZpcOgYBSmVsLo2DhadaIByu6lhs33Z-0Rxf16dTPl1r9YU1YUkeOE3cCFNJXEoDxN_WghklARGBZEvbWl6weI68UMUymEp7MHDy2BwQ8EnlgIHTdGhOyKYYnY4nlxDyl80IwE2WXwDhmg1Qitr9_yOcD-sm14Do8CV5MTBI-i2N_BV55sNrsn0-5Mh3SD--nd9jhVugYzyTGAZh3DmFK2ez8Iua0NKrG-DddNKne_QkdD3-b_aVnqyVmFNgtBQYIv0BG8tv-CgeGKGzjl6iokF8ceLvsLLj7xtyfXjwc3ycD80VcleLeoGp4E4p60rvHa8chhlFY3wrATUr1JQRTBWeN8xwCLLqzoItW8Gt9cb6Rhi2S7bCLPh3hCpeC8dQ971DdTDg7LbufCeAaxgDFCgjbDm72g3K49gA405DBII20WgTjTbR0SYabZKRfPXWfVLeeOT572i41bOomx0vgDfpwZv0Y96Ukf2l2TWsM0yemOBn_Vyj0D12KuJVRt4mN1h9qoJNGhPKGREbDrIxls074fYmanlzoOulqt8_xeA_kOc4J6mY-CPZWvzp_SegTAu7F1cH_B5Ny38nvQ5j
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cisplatin+Concentrations+in+Long+and+Short+Duration+Infusion%3A+Implications+for+the+Optimal+Time+of+Radiation+Delivery&rft.jtitle=Journal+of+clinical+and+diagnostic+research&rft.au=Pradeep+Rajkumar&rft.au=Binu+Susan+Mathew&rft.au=Saikat+Das&rft.au=Rajesh+Isaiah&rft.date=2016-07-01&rft.pub=JCDR+Research+and+Publications+Private+Limited&rft.issn=2249-782X&rft.eissn=0973-709X&rft.volume=10&rft.issue=7&rft.spage=XC01&rft.epage=XC04&rft_id=info:doi/10.7860%2FJCDR%2F2016%2F18181.8126&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_0073588a144b473a980288758bdb5037
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2249-782X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2249-782X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2249-782X&client=summon